Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

CLINICAL OUTCOMES OF IVUS-GUIDED VERSUS ANGIOGRAPHY-GUIDED PERCUTANEOUS CORONARY INTERVENTION IN PATIENTS WITH CHRONIC KIDNEY DISEASE: A PROSPECTIVE COMPARATIVE STUDY

View through CrossRef
Background:Patients with chronic kidney disease undergoing percutaneous coronary intervention are at increased risk of contrast-associated acute kidney injury and adverse cardiovascular events. Intravascular ultrasound guidance may improve procedural optimization and reduce contrast exposure compared with conventional angiography-guided PCI.Methods:This prospective comparative study included 158 patients with chronic kidney disease and significant coronary artery disease requiring PCI. Patients were divided into two groups: IVUS-guided PCI group (n=79) and angiography-guided PCI group (n=79). Baseline demographic, clinical, renal, cardiac, angiographic, procedural, and follow-up outcome data were recorded. The primary outcome was contrast-associated acute kidney injury, defined as an absolute rise in serum creatinine of ≥0.3 mg/dL or a relative increase of ≥50% from baseline within 48–72 hours after contrast exposure. Secondary outcomes included contrast volume, procedural success, worsening renal function, need for dialysis, length of hospital stay, and major adverse cardiac events.Results:Baseline demographic, renal, cardiac, and angiographic characteristics were comparable between the two groups. The mean contrast volume was significantly lower in the IVUS-guidedPCI group compared with the angiography-guided PCI group (72.4 ± 22.6 mL vs 108.7 ± 31.5 mL; p<0.001). The incidence of contrast-associated acute kidney injury was significantly lower in the IVUS-guided PCI group (5.1% vs 15.2%; p=0.034). Worsening renal function was also lower in the IVUS-guided group (7.6% vs 19.0%; p=0.035), and hospital stay was shorter (4.2 ± 1.4 days vs 5.1 ± 2.0 days; p=0.001). Follow-up major adverse cardiac events were significantly lower in the IVUS-guided group compared with theangiography-guided group (6.3% vs 17.7%; p=0.028).Conclusion:IVUS-guided PCI was associated with lower contrast use, reduced contrast-associated acute kidney injury, better renal outcomes, shorter hospital stay, and lower follow-up major adverse cardiacevents compared with angiography-guided PCI in patients with chronic kidney disease. IVUS-guided PCI may be considered a safer and more effective revascularization strategy in CKD patients, particularly in those at high risk of contrast-related renal injury.
Title: CLINICAL OUTCOMES OF IVUS-GUIDED VERSUS ANGIOGRAPHY-GUIDED PERCUTANEOUS CORONARY INTERVENTION IN PATIENTS WITH CHRONIC KIDNEY DISEASE: A PROSPECTIVE COMPARATIVE STUDY
Description:
Background:Patients with chronic kidney disease undergoing percutaneous coronary intervention are at increased risk of contrast-associated acute kidney injury and adverse cardiovascular events.
Intravascular ultrasound guidance may improve procedural optimization and reduce contrast exposure compared with conventional angiography-guided PCI.
Methods:This prospective comparative study included 158 patients with chronic kidney disease and significant coronary artery disease requiring PCI.
Patients were divided into two groups: IVUS-guided PCI group (n=79) and angiography-guided PCI group (n=79).
Baseline demographic, clinical, renal, cardiac, angiographic, procedural, and follow-up outcome data were recorded.
The primary outcome was contrast-associated acute kidney injury, defined as an absolute rise in serum creatinine of ≥0.
3 mg/dL or a relative increase of ≥50% from baseline within 48–72 hours after contrast exposure.
Secondary outcomes included contrast volume, procedural success, worsening renal function, need for dialysis, length of hospital stay, and major adverse cardiac events.
Results:Baseline demographic, renal, cardiac, and angiographic characteristics were comparable between the two groups.
The mean contrast volume was significantly lower in the IVUS-guidedPCI group compared with the angiography-guided PCI group (72.
4 ± 22.
6 mL vs 108.
7 ± 31.
5 mL; p<0.
001).
The incidence of contrast-associated acute kidney injury was significantly lower in the IVUS-guided PCI group (5.
1% vs 15.
2%; p=0.
034).
Worsening renal function was also lower in the IVUS-guided group (7.
6% vs 19.
0%; p=0.
035), and hospital stay was shorter (4.
2 ± 1.
4 days vs 5.
1 ± 2.
0 days; p=0.
001).
Follow-up major adverse cardiac events were significantly lower in the IVUS-guided group compared with theangiography-guided group (6.
3% vs 17.
7%; p=0.
028).
Conclusion:IVUS-guided PCI was associated with lower contrast use, reduced contrast-associated acute kidney injury, better renal outcomes, shorter hospital stay, and lower follow-up major adverse cardiacevents compared with angiography-guided PCI in patients with chronic kidney disease.
IVUS-guided PCI may be considered a safer and more effective revascularization strategy in CKD patients, particularly in those at high risk of contrast-related renal injury.

Related Results

Early Onset of Coronary Subclavian Steal Syndrome: A Case Report and Literature Review
Early Onset of Coronary Subclavian Steal Syndrome: A Case Report and Literature Review
Abstract Introduction Coronary subclavian steal syndrome (CSSS) is a rare phenomenon that often goes undiagnosed and causes severe complications, including death. This report prese...
Rethinking Anticoagulation in Kidney Disease and Kidney Transplantation
Rethinking Anticoagulation in Kidney Disease and Kidney Transplantation
BackgroundA clinical dilemma exists in patients with CKD, ESKD, and after kidney transplantation, as they face concurrent risks of both thromboembolic and hemorrhagic complications...
Emerging Evidence of IgG4-Related Disease in Pericarditis: A Systematic Review
Emerging Evidence of IgG4-Related Disease in Pericarditis: A Systematic Review
Abstract Introduction Immunoglobulin G4-related disease (IgG4-RD) is a recently identified immune-mediated condition that is debilitating and often overlooked. While IgG4-RD has be...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract Introduction Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...

Back to Top